<DOC>
	<DOCNO>NCT02043665</DOCNO>
	<brief_summary>The purpose trial ass ability CVA21 , either alone ( Part A ) combination pembrolizumab ( Part B ) , reach replicate existing tumor ( spar normal cell ) establish safe multi-dose schedule virus treatment solid tumor enhance expression ICAM-1 and/ DAF receptor occur . This trial consist 2 sequential part : VLA-009 ( Part A ) conduct UK employ CVA21 monotherapy NSCLC , castrate-resistant prostate cancer , melanoma bladder cancer . VLA-009 ( Part B ) conduct US UK employ CVA21 pembrolizumab NSCLC bladder cancer . Both VLA-009A VLA-009B open-label , multi-center , ascend dose escalation ( 3+3 design ) dose-finding signal-seeking study .</brief_summary>
	<brief_title>Systemic Treatment Of Resistant Metastatic Disease Employing CVA21 Pembrolizumab Non-small Cell Lung Cancer Bladder Cancer ( STORM/ KEYNOTE-200 )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>Histologicallyconfirmed ( 1 ) NSCLC , ( 2 ) bladder cancer , ( 3 ) castrateresistant prostate cancer metastatic , ( 4 ) stage 3C stage 4 melanoma . VLA009A : Locally advance and/or metastatic disease curative surgery and/or radiation therapy possible judged candidate current standard care treatment . VLA009B : locally advance and/or metastatic disease judge candidate pembrolizumab use combination CVA21 . All subject Cohort 3 Phase 2 dose ( P2D ) must lesion accessible FNA core open biopsy day 8 first treatment cycle . No CVA21 neutralise antibody ( â‰¤ 1:16 ) Measurable evaluable disease Second primary malignancy within past 2 year ( except nonmelanoma skin cancer , situ carcinoma cervix , breast cancer ) Concurrent immunosuppressive therapy know immunosuppressive disease primary tumour</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>CAVATAK</keyword>
	<keyword>KEYNOTE-200</keyword>
	<keyword>pembrolizumab</keyword>
	<keyword>lung cancer</keyword>
	<keyword>bladder cancer</keyword>
</DOC>